1. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Patridge EE, Look KY, Clarke-Pearson DL, Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with Stage III and Stage IV ovarian cancer. N Engl J Med. 1996;334 :1-6.

2. Piccart MJ, Bertelsen K, Stuart J, Mangioni C, Simonsen E, James K, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson R, Swenerton K, Trope C, Nardi M, kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lidvall B, Bacon M, Birt A, Andersen J, Zee B, Paul J, Pecorelli S, Baron B, McGuire W. Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer 2003; 13 (2) :144-8.

3. du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, Bauknecht T, Richter B, Warm M, Schoder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J, Arbeitsgemeinschaft Gynkologische Onkologie Ovarian Cancer Study Group. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003; 95:1320-9.

4. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R; Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected Stage III ovarian cancer : a Gynecologic Oncoloogy Group study. J Clin Oncol 2003; 21:3194-200.

5. Pignata S, Scambia G, Ferrandina G, Savarese A, Sorio R, Breda E, Gebbia V, Musso P, Frigerio L, Del Medico P, Lombardi AV, Febbraro A, Scollo P, Ferro A, Tamberi S, Brandes A, Ravaioli A, Valerio MR, Aitini E, Natale D, Scaltriti L, Greggi S, Pisano C, Lorruso D, Salutari V, Legge F, DI Maio M, Morabito A, Gallo C, Perrone F. Carboplatin pus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer : the MITO-2 randomized Phase III trial. J Clin Oncol 2013; 20 : 33628-35.

6. The International Collaborative Ovarian Neoplasm (ICON) Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer : the ICON 3 randomised trial. The Lancet 2002; 360:505-17.

7. Aravantinos G, Fountzilas G, Bamias A, Grimani I, Rizos S, Kalofonos HP, Skarlos DV, Economopoulos T, Kosmidis PA, Stathopoulos GP, Briasoulis E, Pectasides D, Samantas E, Timotheadou E, Padadimitriou C, Papanikolaou A, Onyenadum A, Papakostas P, Bafaloukos D, Dimopoulos MA; Hellenic Cooperative Oncology Groupp study. Carboplatin and paclitaxel versus cisplatin, paclitaxel and doxorubicin for first-line chemotherapy of advanced ovarian cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. Eur J Cancer 2008; 44(15):2169-77.

8. Bolis G, Scarfone G, Raspagliesi F, Mangili G, Danese S, Scollo P, Lo Russo D, Villa A, Aimone PD, Scambia G. Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III-IV epithelial ovarian cancer a multicenter, randomized study. Eur J Cancer 2010; 46(16):2905-12.

9. Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, Colombo N, Fowler JM, Argenta PA, De Geest K, Mutch DG, Burger RA, Swart AM, Trimble EL, Accario-Winslow C, Roth LM. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol 2009; 27(9):1419-25.

10. du Bois A, Herrstedt J, Hardy-Bessard Ac, Muller HH, Harter P, Kirstensen G, Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. J Clin ONcol 2010;28(27);4162-9.

11. Hoskins P, Vergote I, Cervantes A, Tu D, Stuart G, Zola P, Poveda A, Provencher D, Katsaros D, Ojeda B, Ghatage P, Grimshaw R, Casado A, Elit L, Mendiola C, Sugimoto A, DHondt V, Oza A, Germa JR, Royo M, Brotto L, Chen D, Eisenhauer EA. Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatinpaclitaxel. J Natl Cancer Inst 2010;102(20):1547-56.

12. Norton L. Theoretical concepts and the emerging roles of taxanes in adjuvant therapy. Oncologist 2001;6 (suppl 3):30-35.

13. Katsumata N, Yasuda M, Isonishi S, Takahashi F, Michimae H, Kimura E, Aoki D, Jobo T, Kodama S, Terauchi F, Sugiyama T, Ochiai K; Japanese Gynecologic Oncology Group. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomized controlled, open-label trial. Lancet Oncol 2013;14:1020-6.

14. Harano K, Terauchi F, Katsumata N, Takashi F, Yasuda M, Takano M, Yamamoto Y, Sugiyama T. Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as first-line treatment for stage II-IV ovarian cancer. Ann Oncol 2014; 25:251-7.

15. Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S, Bologna A, Weber B, Raspagliesi F, Panici PB, Cormio G, Sorio R, Cavazzini MG, Ferrandina G, Breda E, Murgia V, Sacco C, Cinieri S, Salutari V, Ricci C, Pisano C, Greggi S, Lauria R, Lorusso D, Marchetti C, Selvaggi L, Signoriello S, Piccirillo MC, Di Maio M, Perrone F; Multicentre Italian Trials in Ovarian cancer (MITO-7); Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens et du sein (GINECO); Mario Negri Gynecologic Oncology (MaNGO); European Network of Gynaecological Oncological Trial Groups (ENGOT-OV-10); Gynecologic Cancer InterGroup (GCIG) Investigators.Lancet Oncol. 2014;15(4):396-405.

16. Dalton HJ, Yu X, Hu L, Kapp DS, Benjamin I, Monk BJ, Chan JK. An economic analysis of dose-dense weekly paclitaxel plus carboplatin versus every 3-week paclitaxel plus carboplatin in the treatment of advanced ovarian cancer. Gynecol Onco 2012; 124 (2) :199-204.

17.SIGN- Management of epithelial ovarian cancer. A national clinical guideline. SIGN publication no.135 by the Scottish Intercollegiate Guidelines Network (SIGN, UK). Available at Accessed 1 Feb 2014.

18.NCCN guidelines for Ovarian Cancer Version 2.2013 ( Accessed 1 Feb 2014.

19. Armstrong DK, Undy B, Wenzel L, Huang HQ, Baerfen R, Lele S, Copeland LJ, Walker JL, Burger RA; Gynaecologic Oncology Group. Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer. N Engl J Med 2006; 354:34-43.

20. Trimble EL and Christian MC. National Cancer Institute-United States strategy regarding intraperitoneal chemotherapy for ovarian cancer. Int J Gynecol Cancer. 2008 Mar-Apr;18 Suppl 1:26-8.

21. Ovarian Cancer : the recognition and initial management of ovarian cancer (CG122) by the National Institute of Health and Clinical excellence (NICE, UK). ( Accessed1 Feb 2014.

22.JA Ledermann, Raja FA. Fotopoulou C, Gonzalez-Martin A, Colombo N & Sessa C on behalf of the ESMO Guidelines Working Group. Newly diagnosed and relapsed epithelial ovarian carcinoma :ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2013;24(Suppl 6):vi 24-32.

23. Best Clinical Practice Gynaecological Cancer Guidelines 2009. Greater Metropolitan Clinical Taskforce (GMCT, Australasia). Accessed 1 Feb 2014.

24. NCIC Clinical Trials Group. Comparing combination chemotherapy regimens in treatingpatients with stage IIB, stage IIC, stage III, or stage IV ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer. Available at: Accessed on 22 May 2014.

25. Gynecologic Oncology Trial & Investigation Consortium. Intraperitoneal therapy for ovarian cancer with carboplatin trial (iPocc). Available at: http:// Accessed on 22 May 2014.

26. National Cancer Institute. Bevacizumab and intravenous or intraperitoneal chemotherapy in treating patients with stage II-III ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer. Available at: Accessed on 22 May 2014.

27. Havrilesky LJ, Secord AA, Darcy KM, Armstrong DK, Kulasingnam S; Gynecologic Oncology Group. Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2008 Sep 1;26(25):4144-50. doi: 10.1200/JCO.2007.13.1961.

28. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H< Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ, Liang SX; Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365(26):2473-2483.

29. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurxeder C, du Bois A, Sehouli J, Kimmig R, Stahle A, Collinson F, Essapen S, Gourley C, Lortholary S, Selle F, Mirza MR, Leiminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM; ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365(26):2484-2496.

30. Stark D1, Nankivell M, Pujade-Lauraine E, Kristensen G, Elit L, Stockler M, Hilpert F, Cervantes A, Brown J, Lanceley A, Velikova G, Sabate E, Pfisterer J, Carey MS, Beale P, Qian W, Swart AM Oza A, Perrent T. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. Lancet Oncol. 2013;14(3):236-243.

31. Monk BJ, Huang HQ, Burger RA, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Liang SX, Wenzel L. Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 2013;128(3):573-578.

32. Cohn DE, Kim KH, Resnick KE, OMalley DM, Straughan JM Jr. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. J Clin Oncol 2011;29(10):1247-1251.

33. Lesnock JL, Farris C, Krivak TC,Smith KJ, Markman M. Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer. Gynecol Oncol 2011;122(3):473-478

34. Chan JK, Herzog TJ, Hu L, Kiet T, Kapp DS, Yu X. Bevacizumab in treatment of high-risk ovarian cancer--a cost-effectiveness analysis. Oncologist 2014;19(5):523-527.

35. Mehta DA, Hay JW. Cost-effectiveness of adding bevacizumab to first line therapy for patients with advanced ovarian cancer. Gynecol Oncol 2014;132(3):677-683.

36. Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, COens C, Verleye L, Stuart GC, Pecorelli S, Reed NS; European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010 Sept 2;363 (10):943-53.

37. Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener HC, Luesley D, Perren T, Bannoo S, Mascarenhas M, Dobbs S, Essapen S, Twigg J, Herod J, McCluggage G, Parmar M, Swart A. Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: Results from the MRC CHORUS trial. J Clin Oncol, 2013 (suppl, abstr 5500)

38. Cochrane Database syst Rev 2012 Aug 15;8:CD005343.